NEW YORK (GenomeWeb News) – UK molecular diagnostics firm Lumora today announced a licensing deal to develop tests for veterinary diagnostics company Biogal Galed Labs.
The deal provides Israel-based Biogal access to Lumora's technologies, including BART, or Bioluminescent Assay in Real Time, as well as its expertise in test development, reader technologies, and manufacturing, Lumora said. Initially, Lumora will develop a test for leptospirosis, a zoonotic bacterial infection that is transmitted through urine.
Development of other tests is expected to follow.
"With the leptospirosis test progressing through development, we have already initiated work on a series of additional assays in the planned development pipeline," Laurence Tisi, CEO of Lumora, said in a statement.
Financial terms of the deal were not disclosed.